Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, is today holding its Annual General Meeting (“AGM”) of shareholders and, immediately following the AGM, will hold a shareholder event comprising a business review and presentations from the senior management teams of the Therapeutics and Diagnostics Divisions with Q&A.
Avacta Chief Executive, Alastair Smith, will present a business review which will outline the commercial and corporate strategy of the Group and its divisions. The Business Update (11:00-12:00 BST) will be simultaneously streamed live on the Investor Meet Company (“IMC”) platform. Investors who already follow Avacta on IMC will automatically be invited to join the live stream. Investors who do not have an IMC account can sign up for free at https://www.investormeetcompany.com/avacta-group-plc/register-investor and then click “Add to meet” on the Avacta page in order to receive an invitation.
A buffet lunch will be accompanied by poster presentations covering AVA6000, AVA3996, Affimer® Therapeutics and the Launch Diagnostics business will also be present at a booth. This will provide investors with the opportunity to meet the senior management teams.
After lunch, the Company will discuss the AVA6000 Phase 1a clinical data that was recently presented at the Company’s Science Day and will present the Diagnostics Division strategy.
Following closing comments and a final Q&A session, the event will end at 14:00 BST.
All presentation materials, including slide decks and posters, are now available at https://avacta.com/investors/investor-resources/